INTRODUCTION: Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease. METHODS: We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting. RESULTS: NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic DPP4 mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (n = 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2-10.21), p = 0.022. CONCLUSIONS: This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease's progression in established NAFLD.
INTRODUCTION:Dipeptidyl peptidase 4 (DPP4) levels are associated to metabolic and cardiovascular diseases in humans; initial evidence reported a relationship between DPP4 and chronic liver diseases. Aim of this study was to investigate hepatic and systemic DPP4 levels/activity in relation to NAFLD/NASH in individuals with and without metabolic disease. METHODS: We recruited fifty-two obese individuals undergoing bariatric surgery and intra-operative liver biopsy at Sapienza University, Rome, Italy. The association between DPP4 levels/activity and NAFLD was also evaluated in 126 non-obese individuals recruited in the same setting. RESULTS: NAFLD patients had significantly higher circulating DPP4 activity than no-NAFLD in both the obese and non-obese cohorts; plasma DPP4 activity and levels linearly correlated with steatosis grade and inflammation at the liver biopsy. Hepatic DPP4 mRNA was not associated to either its circulating levels/activity or NAFLD. In the multivariate logistic regression analysis on all the study participants (n = 178), higher circulating DPP4 activity was associated with NAFLD independently of potential confounders with OR (95% CI): 3.5 (1.2-10.21), p = 0.022. CONCLUSIONS: This study demonstrates the coexistence of increased plasma DPP4 levels and activity in NAFLD. Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease's progression in established NAFLD.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Hepatology Date: 2012-06 Impact factor: 17.425
Authors: Christian Baumeier; Sophie Saussenthaler; Anne Kammel; Markus Jähnert; Luisa Schlüter; Deike Hesse; Mickaël Canouil; Stephane Lobbens; Robert Caiazzo; Violeta Raverdy; François Pattou; Emma Nilsson; Jussi Pihlajamäki; Charlotte Ling; Philippe Froguel; Annette Schürmann; Robert W Schwenk Journal: Diabetes Date: 2016-10-10 Impact factor: 9.461
Authors: Paul Angulo; Elisabetta Bugianesi; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Francisco Barrera; Svanhildur Haflidadottir; Christopher P Day; Jacob George Journal: Gastroenterology Date: 2013-07-13 Impact factor: 22.682
Authors: Christian Baumeier; Luisa Schlüter; Sophie Saussenthaler; Thomas Laeger; Maria Rödiger; Stella Amelie Alaze; Louise Fritsche; Hans-Ulrich Häring; Norbert Stefan; Andreas Fritsche; Robert Wolfgang Schwenk; Annette Schürmann Journal: Mol Metab Date: 2017-08-04 Impact factor: 7.422
Authors: Ákos Nádasdi; György Sinkovits; Ilona Bobek; Botond Lakatos; Zsolt Förhécz; Zita Z Prohászka; Marienn Réti; Miklós Arató; Gellért Cseh; Tamás Masszi; Béla Merkely; Péter Ferdinandy; István Vályi-Nagy; Zoltán Prohászka; Gábor Firneisz Journal: Biomark Med Date: 2022-02-23 Impact factor: 2.851
Authors: Jing Ren; Xiaoyu Wang; Christine Yee; Mark D Gorrell; Susan V McLennan; Stephen M Twigg Journal: Molecules Date: 2022-01-22 Impact factor: 4.411
Authors: Gilberto Vargas-Alarcón; Maria Del Carmen González-Salazar; Adrian Hernández-Díaz Couder; Fausto Sánchez-Muñoz; Julian Ramírez-Bello; José Manuel Rodríguez-Pérez; Rosalinda Posadas-Sánchez Journal: Diagnostics (Basel) Date: 2022-07-15